Alain Faivre-Chauvet - JoVE Visualize

Showing results (61-70 of 76) with videos related to

Pageof 8

Sort By:

European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024

Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastasesAlexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.

Clinical Nuclear Medicine|December 14, 2020

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.

Inorganic Chemistry|January 26, 2021

Cyclam-Based Chelators Bearing Phosphonated Pyridine Pendants for 64Cu-PET Imaging: Synthesis, Physicochemical Studies, Radiolabeling, and BioimagingRichard C Knighton, Thibault Troadec, Valérie Mazan, et al.

Cancers|December 10, 2021

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and SafetyJudith Anna Delage, Silvano Gnesin, John O Prior, et al.

European Journal of Nuclear Medicine and Molecular Imaging|June 25, 2021

Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE studyJonathan Vigne, Damien Peyronnet, Julien Leenhardt, et al.

International Journal of Molecular Sciences|May 30, 2019

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003

Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trialFrançoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.

Frontiers in Medicine|December 8, 2015

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.

Pharmaceutics|July 29, 2023

Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple MyelomaCassandra Métivier, Patricia Le Saëc, Joëlle Gaschet, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.

Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:

Pageof 8

European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024

Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastasesAlexandre Lugat, Nicolas Chouin, Florian Chocteau, et al.

Clinical Nuclear Medicine|December 14, 2020

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.

Inorganic Chemistry|January 26, 2021

Cyclam-Based Chelators Bearing Phosphonated Pyridine Pendants for 64Cu-PET Imaging: Synthesis, Physicochemical Studies, Radiolabeling, and BioimagingRichard C Knighton, Thibault Troadec, Valérie Mazan, et al.

Cancers|December 10, 2021

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and SafetyJudith Anna Delage, Silvano Gnesin, John O Prior, et al.

European Journal of Nuclear Medicine and Molecular Imaging|June 25, 2021

Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE studyJonathan Vigne, Damien Peyronnet, Julien Leenhardt, et al.

International Journal of Molecular Sciences|May 30, 2019

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003

Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trialFrançoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.

Frontiers in Medicine|December 8, 2015

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.

Pharmaceutics|July 29, 2023

Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple MyelomaCassandra Métivier, Patricia Le Saëc, Joëlle Gaschet, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.

Pageof 8